DBP’s scientific paper about MGMT and Temodex is in PubMed
Double Bond Pharmaceutical’s pilot study on whether MGMT, the well-known biomarker in glioma treatment, can affect the overall survival of brain cancer patients treated with Temodex is now available online at PubMed as “ahead of print”. The paper was, as earlier reported, peer-reviewed by an expert panel and thereafter accepted for publication in Neoplasma. The hard copy of the article in the journal will be issued in the beginning of 2019.
"The study results provide an important insight into the potential magnitude of the therapeutic value of Temodex and SI053", - says Igor Lokot, CEO of Double Bond Pharmaceutical. "Based on these preliminary data we expect that the local administration of temozolomide can potentially be a new treatment option for brain tumor patients who are resistant to systemically administered temozolomide".
Read the article here: https://www.ncbi.nlm.nih.gov/pubmed/30569719
More about Temodex: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. The product has a working name SI-053 in DBP pipeline. Video presentation: https://youtu.be/iweOQPq316o
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.